What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Internal medicine, Breast cancer, Oncology, Tumor-infiltrating lymphocytes and Cancer research are her primary areas of study.
Her Internal medicine study frequently involves adjacent topics like Surgery.
She has included themes like Pathology and Gene expression profiling in her Breast cancer study.
The various areas that Sherene Loi examines in her Oncology study include Cancer, Clinical trial, Chemotherapy, Palbociclib and Fulvestrant.
Her Tumor-infiltrating lymphocytes study combines topics in areas such as Immune checkpoint, Triple Negative Breast Neoplasms, Biomarker and FOXP3.
Her research investigates the link between Cancer research and topics such as Mutation that cross with problems in PI3K/AKT/mTOR pathway and ERBB3.
Her most cited work include:
- Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis (1527 citations)
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 (1126 citations)
- Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer (1037 citations)
What are the main themes of her work throughout her whole career to date?
Sherene Loi focuses on Internal medicine, Breast cancer, Oncology, Cancer and Cancer research.
Internal medicine connects with themes related to Placebo in her study.
Her study in Breast cancer is interdisciplinary in nature, drawing from both Clinical trial, Pathology and Immunotherapy.
Her Oncology research incorporates themes from Pembrolizumab, Tumor-infiltrating lymphocytes, Neoadjuvant therapy and Hazard ratio.
Sherene Loi has included themes like Biomarker, Adverse effect and Randomized controlled trial, Surgery in her Cancer study.
Her Cancer research study combines topics from a wide range of disciplines, such as Mutation, Tumor microenvironment, T cell, Immune system and PTEN.
She most often published in these fields:
- Internal medicine (71.04%)
- Breast cancer (69.42%)
- Oncology (65.11%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (71.04%)
- Oncology (65.11%)
- Breast cancer (69.42%)
In recent papers she was focusing on the following fields of study:
Sherene Loi mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Cancer research.
Her Internal medicine study which covers Placebo that intersects with Locally advanced and Hazard ratio.
She has researched Oncology in several fields, including Pembrolizumab, Chemotherapy, Stage, Biomarker and Nivolumab.
Her work deals with themes such as Adverse effect, Cohort and Immunotherapy, which intersect with Breast cancer.
Her studies examine the connections between Cancer and genetics, as well as such issues in Confidence interval, with regards to Proportional hazards model.
Her Cancer research research is multidisciplinary, incorporating elements of Stroma, Tumor microenvironment, Immune system, Cancer cell and Antigen.
Between 2019 and 2021, her most popular works were:
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (203 citations)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (196 citations)
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (106 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Sherene Loi mostly deals with Internal medicine, Breast cancer, Oncology, Cancer research and Immunotherapy.
In her study, Hazard ratio and Pertuzumab is strongly linked to Placebo, which falls under the umbrella field of Internal medicine.
Her Breast cancer research integrates issues from Clinical trial, Tumor-infiltrating lymphocytes and Predictive biomarker.
Her work on Progression-free survival as part of general Oncology research is frequently linked to Clinical Practice, bridging the gap between disciplines.
The study incorporates disciplines such as Tumor microenvironment, Cancer, Immune system, Karyotype and Antigen in addition to Cancer research.
The Immunotherapy study combines topics in areas such as Antibody, CD8 and Disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
